Business Wire·Oct 28, 2025, 8:00 AM ET

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

bioAffinity Technologies (NASDAQ: BIAF, BIAFW) received acceptance of a patent application from IP Australia for its proprietary platform assessing lung health & predicting multiple lung diseases.
The accepted application, AU 2019253111 titled "System and Method for Determining Lung Health," utilizes flow cytometry combined with fluorescent probes to detect cellular & molecular signatures of lung diseases.
The patent application will automatically issue three months after acceptance unless a third party files an opposition.
bioAffinity's global patent estate now includes 18 awarded patents & 33 pending patents across jurisdictions such as the U.S., Canada, China, France, Germany, Japan, & the UK.
The company's flagship product, CyPath ® Lung, remains a noninvasive test using flow cytometry & AI to identify malignancy in patient sputum samples.
Clinical results for CyPath ® Lung demonstrated 92% sensitivity, 87% specificity, & 88% accuracy in detecting lung cancer in high-risk patients with nodules under 20 millimeters.
CyPath ® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.